Single answer
Is Allogene Therapeutics Inc (ALLO) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Allogene Therapeutics Inc is $29.00, which is $26.47 (1,046.25%) above the current price today's price.
Low target: $7.00 | High target: $55.00
Company snapshot
A quick overview of the business and its public profile.
Allogene Therapeutics Inc a clinical stage immunooncology company develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer It develops manufactures and commercializes UCART19 an allogeneic chimeric antigen receptor CAR T cell product candidate for the treatment of pediatric and adult patients with RR CD19 positive Bcell ALL The company also develops ALLO501 an antiCD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of RR nonHodgkin lymphoma and ALLO501A which is in Phase III clinical trial for the treatment RR large Bcell lymphoma or transformed follicular lymphoma In addition it is developing ALLO715 an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating RR multiple myeloma ALLO605 an allogeneic CAR T cell product candidate for the treatment of multiple myeloma ALLO647 an antiCD52 monoclonal antibody CD70 to treat renal cell cancer ALLO819 an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors The company has license and collaboration agreements with Pfizer Inc Servier Cellectis SA and Notch Therapeutics Inc as well as clinical trial collaboration agreement with SpringWorks Therapeutics Inc It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates The company was incorporated in 2017 and is headquartered in South San Francisco California
Website: https://www.allogene.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.19. Cash flow to debt ratio: -1.86. Net profit margin: 0.00%. Inflation risk score: high (0.75/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Allogene Therapeutics Inc is $6.2M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Allogene Therapeutics Inc 10 years ago, but if you had invested on 2018-10-11 when the price was $25.00, you would have made a loss of $22.47 per share or 89.88%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.